-
DARA BioSciences Presented Positive Results of Its Phase I Study for DB959 at the American Diabetes Association Scientific Session
Tuesday, June 28, 2011 - 8:49am | 203Today DARA BioSciences (Nasdaq: DARA) announced the positive results of a randomized, placebo-controlled, double-blind, escalating single-dose study to evaluate the safety, tolerability, pharmacokinetics and food effect of DB959Na in healthy male and female volunteers. The presentation provided...
-
UPDATE: Bank of America Merrill Lynch Initiates Momenta Pharmaceuticals at Underperform
Tuesday, June 28, 2011 - 8:44am | 114Bank of America Merrill Lynch is out with its report today on Momenta Pharmaceuticals (NASDAQ: MNTA), initiating MNTA at Underperform. In a note to clients, Bank of America Merrill Lynch writes, "We believe MNTA could underperform vs. other stocks in our coverage as: 1) potential competition on...
-
Wedbush Reiterates OP Rating on SIGA Technologies
Tuesday, June 28, 2011 - 8:43am | 108Wedbush is reiterating its Outperform rating on shares of SIGA Technologies (NASDAQ: SIGA). “We derive our $23/share price target by applying an 11x multiple to our estimate of the net profits from 2015 ST-246 US sales (50% net after tax margin), discounted 20% annually, added to the estimated...
-
Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize a New Fixed-Dose Combination of Cobicistat and Prezista
Tuesday, June 28, 2011 - 8:32am | 92Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a license agreement with Tibotec Pharmaceuticals for the development and commercialization of a new fixed-dose antiretroviral combination product containing Gilead's cobicistat and Tibotec's protease inhibitor Prezista® (...
-
Benzingas Top Pre-Market NASDAQ Gainers
Tuesday, June 28, 2011 - 8:18am | 126Westport Innovations Inc (NASDAQ: WPRT) shares advanced 6.23% to $22.85 in the pre-market session. WPRT signed an agreement with General Motors (NYSE: GM) to help develop advanced natural gas engine technology. SIGA Technologies Inc (NASDAQ: SIGA) shares advanced 5.34% to $11.45 in the pre-market...
-
Benzingas Top Pre-Market NASDAQ Losers
Tuesday, June 28, 2011 - 8:11am | 111Swisher Hygiene Inc (NASDAQ: SWSH) dipped 4.90% to $5.24 in the pre-market session. SWSH acquired Prinova Co Inc. Icagen Inc (NASDAQ: ICGN) dropped 1.90% to $6.21 in the pre-market trading. Pfizer Inc (NYSE: PFE) reported that it is considering a strategic transaction with Icagen. ASML Holding...
-
Alnylam Presents New Data from ALN-TTR Program at Peripheral Nerve Society Meeting; Remain On Track To Report Data From Our Phase I Trial
Tuesday, June 28, 2011 - 8:08am | 239Alnylam Pharmaceuticals (Nasdaq: ALNY) announced today that it is presenting new data from its ALN-TTR program at the 2011 Peripheral Nerve Society Meeting being held in Potomac, Maryland. The company is reporting results from a natural history study which was designed to measure blood levels of...
-
Sinovac Commences Phase II Clinical Trial for EV71 Vaccine
Tuesday, June 28, 2011 - 8:02am | 80Sinovac Biotech Ltd. (Nasdaq: SVA) announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). The safety observation results from the EV71 vaccine Phase I trial completed in May 2011 showing good...
-
Bank of America Merrill Lynch Discusses Amgen
Tuesday, June 28, 2011 - 7:31am | 156Bank of America Merrill Lynch has a Neutral rating and a $62 price target on shares of Amgen (NASDAQ: AMGN). In a note to clients, Bank of America Merrill Lynch writes, "AMGN opted to hold off until its 2Q earnings call with explicit new financial expectations for its erythropoetin stimulating...
-
Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
Tuesday, June 28, 2011 - 7:31am | 88Palatin Technologies, Inc. (NYSE: PTN) announced today that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment...
-
Bank of America Initiates Momenta Pharmaceuticals At Underperform, $19 PO
Tuesday, June 28, 2011 - 7:25am | 26Bank of America has initiated coverage on Momenta Pharmaceuticals (NASDAQ: MNTA) with an Underperform rating and $19 price objective.
-
Oppenheimer Maintains Outperform on Amgen
Tuesday, June 28, 2011 - 7:21am | 105Oppenheimer is out with its report today on Amgen (NASDAQ: AMGN), maintaining Outperform. In a note to clients, Oppenheimer writes, "While the company is facing a number of regulatory and competitive headwinds, we believe revenues from Amgen's core franchises are nearing stabilization. We believe...
-
SIGA Technologies to Sell 1.7M Courses of ST-246 Smallpox Antiviral to National Stockpile
Tuesday, June 28, 2011 - 7:15am | 42SIGA (NASDAQ: SIGA) announced that the Biomedical Advanced Research and Development Authority of the US Department of Health and Human Services has withdrawn the protest filed against the contract it awarded to the company.
-
8 Chart-Busting Trade Setups for Today
Tuesday, June 28, 2011 - 1:31am | 111To Follow-Through, or Not To Follow-Through? That, my friend, is the question hanging over us as we enter into yet another market session this morning. While no on knows if the market will build on yesterday's gains, we do know that below are 8 legitimate trade setups to keep on your radar as the...
-
Mad Money Lightning Round: Cramer Likes Schlumberger, Oracle
Tuesday, June 28, 2011 - 1:02am | 242On CNBC's Mad Money, Jim Cramer said during the Lightning Round that he “wants to own Schlumberger (NYSE: SLB) right here.” He added, “I never get this stock at a discount." Cramer said that he has been “negative on Geron (NASDAQ: GERN) for awhile. It's not worth selling down here but it's not...